Partnerships WuXi Biologics/XDC: GMP manufacturing and IND-enabling work (Dec 2025); Whitehawk Therapeutics: strategic research collaboration (Jul 2026) evaluating PH1 payload with Whitehawk's topoisomerase I inhibitor ADC platform (preclinical)
Indications
Solid tumors (incl. lung, breast, bladder, head & neck, gastric)(Preclinical)
Catalysts
— middle of 2027
Status note Lead program. Trop-2-targeting ADC combining PH1 spliceosome-modulating payload with a proprietary non-cleavable linker. IND-enabling activities underway; GMP manufacturing initiated Dec 2025. 10-K (earlier) guided FIH Phase 1 by late 2026/early 2027; 10-Q restates projection as clinical trials by middle of 2027.
Status note CEACAM5-directed ADC utilizing PH1 payload; earlier in development than lead program. Company plans to advance toward lead product candidate status.
Nomacopan
Stage not disclosed · ActiveModality: bispecific protein
Target C5/leukotriene B4
Indications
not disclosed(Stage not disclosed)
Status note Legacy program suspended December 2024; company seeking a collaborative partner for continued development. Not terminated. Stage/indication detail appears only in the 10-K fallback section and is not populated.
PAS-nomacopan
Stage not disclosed · Active
Target C5, LTB4
Indications
not disclosed(Stage not disclosed)
Status note Legacy program suspended December 2024; company seeking a collaborative partner for continued development. Not terminated. Stage/indication detail appears only in the 10-K fallback section and is not populated.
PHP-303
Stage not disclosed · Active
Target neutrophil elastase
Partnerships Bayer Pharmaceuticals: rights and associated know-how acquired (Mar 2017)
Indications
not disclosed(Stage not disclosed)
Status note Legacy program suspended December 2024; company seeking a collaborative partner for continued development. Not terminated. Stage/indication detail appears only in the 10-K fallback section and is not populated.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.